The American Journal of Medicine
Volume 123, Issue 5 , Pages 454-461 , May 2010

Long-term TNF-α Blockade in Patients with Amyloid A Amyloidosis Complicating Rheumatic Diseases

  • Antonio Fernández-Nebro, MD, PhD

      Affiliations

    • Servicio de Reumatología y Departamento de Medicina de la Facultad de Medicina, Hospital Regional Universitario Carlos Haya, Málaga, Spain
    • Corresponding Author InformationReprint requests should be addressed to Antonio Fernández-Nebro, MD, PhD, Servicio de Reumatología, Hospital Regional Universitario Carlos Haya, Pabellón C: “Hospital Civil,” Plaza del Hospital Civil s/n, 29009, Málaga, Spain
    • ,
  • Alejandro Olivé, MD, PhD

      Affiliations

    • Rheumatology Section, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
    • ,
  • María Carmen Castro, MD, PhD

      Affiliations

    • Servicio de Reumatología, Hospital Universitario Reina Sofía, Córdoba, Spain
    • ,
  • Angela Herranz Varela, MD

      Affiliations

    • Unidad de Investigación, Fundación Española de Reumatología, Madrid, Spain
    • ,
  • Elena Riera, MD

      Affiliations

    • Rheumatology Section, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
    • ,
  • Maria V. Irigoyen, MD

      Affiliations

    • Servicio de Reumatología y Departamento de Medicina de la Facultad de Medicina, Hospital Regional Universitario Carlos Haya, Málaga, Spain
    • ,
  • María Jesús García de Yébenes, MD, PhD

      Affiliations

    • Unidad de Investigación, Fundación Española de Reumatología, Madrid, Spain
    • ,
  • Rosario García-Vicuña, MD, PhD

      Affiliations

    • Rheumatology Service, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain

References 

  1. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:670–675
  2. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007;66:880–885
  3. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003;48:2019–2024
  4. Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118:552–556
  5. Committee BS. BIOBADASER: Spanish registry of adverse events of biological therapies in rheumatic diseases. Rev Esp Reumatol. 2002;29:7
  6. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–2371
  7. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333
  8. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–2127
  9. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319–328
  10. Nakamura T, Higashi S, Tomoda K, et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:518–522
  11. Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000;93:535–542
  12. Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J. 2002;23:157–161
  13. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70:246–256
  14. Browning MJ, Banks RA, Tribe CR, et al. Ten years' experience of an amyloid clinic—a clinicopathological survey. Q J Med. 1985;54:213–227
  15. Triger DR, Joekes AM. Renal amyloidosis—a fourteen-year follow-up. Q J Med. 1973;42:15–40

 Funding: None. The drugs administered to our patients were supplied by the sanitary service as part of the medical care that they normally received.

 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript; however, Antonio Fernández-Nebro has earned $1500 or more per year as speaker or consultant (included all companies) for Abbott, Roche, Schering-Plough, and Bristol-Meyer-Squibb companies during the past 3 years, and Rosario García-Vicuña has earned $1500 or more per year as speaker or consultant (included all companies) for Abbott, Roche, Schering-Plough, and Wyeth companies during the past 3 years.

 Authorship: All authors had access to the data and played a role in writing this manuscript. Dr Fernández-Nebro had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: Fernández-Nebro, García-Vicuña, Olivé. Acquisition of data: Fernández-Nebro, Herranz, Riera, Castro. Analysis and interpretation of data: Fernández-Nebro, García de Yébenes, García-Vicuña, Olivé.

PII: S0002-9343(09)01100-0

doi: 10.1016/j.amjmed.2009.11.010

The American Journal of Medicine
Volume 123, Issue 5 , Pages 454-461 , May 2010

Article Tools

* Image Usage & Resolution